New breast cancer drug for women in Singapore
Singapore, Feb. 18 -- A NEW breast cancer drug shown to significantly reduce the risk of cancer recurrence is being made available to women in Singapore via a Special Access Program.
The drug, NERLYNX (neratinib) is an oral medication taken by women with HER2+ breast cancer who have completed adjuvant trastuzumab-based therapy.
NERLYNX has been shown to significantly reduce the ongoing risk of recurrence in HER2+ early breast cancer patients. The greatest benefit was observed in women who were also hormone-receptor positive (HR+) and treated within 12 months following completion of trastuzumab-based adjuvant therapy. Their five-year risk of recurrence or death was reduced by 42%. In these patients, invasive disease-free survival (iDFS) ...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.